Cheetah Medical develops and sells 100 percent non-invasive fluid management monitoring technologies for use in critical care, operating room and emergency department settings. Its core product, the CHEETAH Starling SV, provides immediate, dynamic assessments of fluid responsiveness to guide clinician treatment decisions. The company reports its systems are used in more than 400 hospitals in the U.S. and in 30 countries worldwide, and cites research linking effective fluid management to shorter ICU stays and lower costs. Cheetah intends to use new capital to retire debt and to invest in sales, marketing and clinical efforts as it works to become a standard of care in management of critically ill patients. Financially, the company secured a $20 million senior secured term loan with $18 million funded at closing and a $2 million tranche available in Q1 2019 subject to milestones. SWK characterized the financing as minimally dilutive, flexible capital to help grow commercial operations and broaden adoption of its hemodynamic monitoring solution. Cheetah Medical, based in Newton, Massachusetts, develops 100% noninvasive hemodynamic monitoring technologies for use in critical care, operating rooms, general care floors, and emergency departments. Its core products—the CHEETAH NICOM and STARLING SV—use a proprietary algorithm to deliver accurate hemodynamic profiles that help clinicians guide volume management and resuscitation decisions. The company cited a recent University of Kansas Medical Center study demonstrating value from stroke-volume–guided resuscitation for sepsis patients as a driver of expected demand. Cheetah says investments in U.S. sales and marketing are already driving "exciting revenue growth" and plans to use new capital to expand its commercial footprint and field presence in the United States. The technologies are positioned to enable more confident therapy decisions, improve patient outcomes, and drive economic efficiencies. Cheetah Medical develops the CHEETAH NICOM Hemodynamic Management System, a non-invasive platform to measure key hemodynamic parameters. The system is currently available in more than 60 countries, including the United States. Leadership includes Chris Hutchison (President and CEO) and Stephen Reeders (Chairman). Financially, the company secured an initial $5M investment provided by growth equity firm HighCape Partners. That $5M represents an extension of a previously announced $9M fundraising round that closed in February 2014. No other financial metrics or future plans were disclosed in the article. Cheetah Medical manufactures a management system that offers a non-invasive means to measure key hemodynamic parameters based on its proprietary bioreactance technology. The company is based in Newton Center, Massachusetts and its system is available in more than 60 countries. On Feb. 25, 2014, Cheetah Medical closed a $9M round of funding. The round was led by Fletcher Spaght Ventures with participation from Springfield Investment Management, MVM Life Science Partners, Robert Bosch Venture Capital and Ascension Health Ventures. The company intends to use the funds to expand its sales and marketing activities in the U.S. and internationally. The business is led by Stephen Reeders and Chris Hutchison (President and CEO, Chairman). Cheetah Medical develops NICOM, a noninvasive hemodynamic monitoring system built on its patented BIOREACTANCE technology. NICOM is FDA cleared and has received a CE Mark. The system is deployed for Goal Directed Fluid Management in over 100 hospitals in the U.S. and is used in other international markets. The company completed a $14.5M financing to support its commercialization efforts. Management said it will use the capital to accelerate NICOM’s commercialization in the U.S. and internationally. The company has appointed Chris Hutchison as President and CEO and William T. Denman, MBChB, FRCA as Chief Medical Officer.

Total raised

$80M

Funding rounds

6

Latest round

Debt Financing

Latest activity

Feb 2019